MX2019013528A - Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). - Google Patents
Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia).Info
- Publication number
- MX2019013528A MX2019013528A MX2019013528A MX2019013528A MX2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A
- Authority
- MX
- Mexico
- Prior art keywords
- sgsh
- variants
- iiia
- sulfamidase
- vectors
- Prior art date
Links
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 title abstract 10
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 title abstract 2
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 title 2
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 title 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 title 1
- 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 abstract 7
- 241000124008 Mammalia Species 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505423P | 2017-05-12 | 2017-05-12 | |
| PCT/US2018/032454 WO2018209317A1 (en) | 2017-05-12 | 2018-05-11 | Sulfamidase (sgsh) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type iiia (mps iiia) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013528A true MX2019013528A (es) | 2020-07-14 |
Family
ID=64104969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013528A MX2019013528A (es) | 2017-05-12 | 2018-05-11 | Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12221635B2 (https=) |
| EP (1) | EP3622060A4 (https=) |
| JP (1) | JP7196099B2 (https=) |
| CN (1) | CN110809626A (https=) |
| AU (1) | AU2018265869C1 (https=) |
| BR (1) | BR112019023869A2 (https=) |
| CA (1) | CA3061925A1 (https=) |
| MX (1) | MX2019013528A (https=) |
| RU (1) | RU2019140862A (https=) |
| WO (1) | WO2018209317A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108728495A (zh) * | 2018-05-31 | 2018-11-02 | 深圳市免疫基因治疗研究院 | 一种Sanfilippo A综合症慢病毒载体、慢病毒及其制备方法和应用 |
| WO2020127678A1 (en) * | 2018-12-20 | 2020-06-25 | Esteve Pharmaceuticals, S.A. | Recombinant vectors for the long term treatment of mucchopolysacharidosis |
| EP3999647A1 (en) * | 2019-07-18 | 2022-05-25 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
| PH12022551247A1 (en) * | 2019-11-22 | 2023-11-13 | Childrens Hospital Philadelphia | Adeno-associated viral vector variants |
| JP2023517230A (ja) * | 2020-03-11 | 2023-04-24 | リモーター セラピューティクス インコーポレイテッド | 中枢神経系全体にわたってタンパク質を散在させるための方法および材料 |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
| WO2023086939A1 (en) * | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
| EP4430201A4 (en) * | 2021-11-12 | 2026-04-08 | Univ Pennsylvania | Gene therapy for the treatment of mucopolysaccharidosis IIIA |
| EP4512892A1 (en) * | 2022-04-19 | 2025-02-26 | JCR Pharmaceuticals Co., Ltd. | Glycoprotein having reduced number of mannose-6-phosphates |
| CN115029360B (zh) * | 2022-05-30 | 2024-08-02 | 上海勉亦生物科技有限公司 | 用于治疗粘多糖贮积症iiia型的转基因表达盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| CA2794196A1 (en) * | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| ES2745470T3 (es) | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| US20170191041A1 (en) * | 2014-07-11 | 2017-07-06 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
-
2018
- 2018-05-11 MX MX2019013528A patent/MX2019013528A/es unknown
- 2018-05-11 RU RU2019140862A patent/RU2019140862A/ru unknown
- 2018-05-11 US US16/611,458 patent/US12221635B2/en active Active
- 2018-05-11 BR BR112019023869A patent/BR112019023869A2/pt unknown
- 2018-05-11 CA CA3061925A patent/CA3061925A1/en active Pending
- 2018-05-11 AU AU2018265869A patent/AU2018265869C1/en active Active
- 2018-05-11 WO PCT/US2018/032454 patent/WO2018209317A1/en not_active Ceased
- 2018-05-11 EP EP18798587.4A patent/EP3622060A4/en active Pending
- 2018-05-11 JP JP2019562293A patent/JP7196099B2/ja active Active
- 2018-05-11 CN CN201880043043.4A patent/CN110809626A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020519629A (ja) | 2020-07-02 |
| JP7196099B2 (ja) | 2022-12-26 |
| BR112019023869A2 (pt) | 2020-06-09 |
| AU2018265869A1 (en) | 2019-11-21 |
| CN110809626A (zh) | 2020-02-18 |
| EP3622060A4 (en) | 2021-02-17 |
| CA3061925A1 (en) | 2018-11-15 |
| RU2019140862A3 (https=) | 2021-08-17 |
| AU2018265869B2 (en) | 2024-10-24 |
| US12221635B2 (en) | 2025-02-11 |
| RU2019140862A (ru) | 2021-06-15 |
| EP3622060A1 (en) | 2020-03-18 |
| WO2018209317A1 (en) | 2018-11-15 |
| US20210324354A1 (en) | 2021-10-21 |
| AU2018265869C1 (en) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013528A (es) | Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). | |
| EP4219728A3 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| SG10201809739QA (en) | Aav vectors for retinal and cns gene therapy | |
| EP4299079A3 (en) | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
| HK1207109A1 (en) | Methods and compositions for treating amyloid deposits | |
| MX2017011615A (es) | Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1. | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| MY190067A (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| MX351865B (es) | Composiciones de raav-guanilato ciclasa y metodos para el tratamiento de la amaurosis congenita de leber 1 (lca1). | |
| PH12018502104B1 (en) | Column-based fully scalable raav manufacturing process | |
| MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
| ZA201701881B (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
| PH12017500098A1 (en) | Suspension compositions of cyclosporin a for subconjunctival and periocular injection | |
| MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
| WO2019222314A8 (en) | Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
| MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
| MX388998B (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| TN2016000460A1 (en) | Aav vectors for retinal and cns gene therapy. | |
| NZ764033A (en) | Aav vectors for retinal and cns gene therapy | |
| HK1241924A1 (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |